Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. - Wikidata - wikimedia - TriplyDB

Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.

Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.

http://www.wikidata.org/entity/Q34084791

about

On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome Prospects for Improving Brain Function in Individuals with Down Syndrome Emerging pharmacotherapies for neurodevelopmental disorders Dissecting Alzheimer disease in Down syndrome using mouse models Timing of therapies for Down syndrome: the sooner, the better Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues Effects of neonatal neural progenitor cell implantation on adult neuroanatomy and cognition in the Ts65Dn model of Down syndrome Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.The use of mouse models to understand and improve cognitive deficits in Down syndrome.Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome Chronic pre-treatment with memantine prevents amyloid-beta protein-mediated long-term potentiation disruption.Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice.Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.Estrogen receptor alpha deficiency protects against development of cognitive impairment in murine lupus.Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).Designer receptors enhance memory in a mouse model of Down syndrome.Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine Age-related neurodegeneration and memory loss in down syndrome.Tc1 mouse model of trisomy-21 dissociates properties of short- and long-term recognition memory.Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome.Is it possible to improve neurodevelopmental abnormalities in Down syndrome?Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome.Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease.Dentate gyrus mediates cognitive function in the Ts65Dn/DnJ mouse model of Down syndrome.Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.Rodent models in Down syndrome research: impact and future opportunities.Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.Effects of positive modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors in a benzodiazepine-induced deficit of spatial discrimination in mice.Alzheimer disease: Treatment of Alzheimer disease in Down syndrome.Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.

P2860

Q22241936-CC88F5ED-CBC0-4D1E-B896-82171DD9D332 Q22252566-EB941CFD-07DB-412E-A2E4-309801AE438A Q24619170-5073F932-9F8E-4542-A47F-88BC026EBCC5 Q26777254-21DCDAF0-F88D-4696-B16D-EBAEBBF75BCF Q26779297-FDD345D1-89D9-4CFC-A764-7593605F7B8D Q26863005-BF9B0068-2E44-40DD-84BC-6A67FB37606B Q27300997-E1C80910-773C-422A-805B-F2A3FD63AABF Q27303804-FF3AC0B7-9895-4BCE-8B83-9AD86E4947EB Q30422188-77840DCA-1BEA-47F2-9A4D-E63991364D2F Q30474023-3D806D79-714B-425A-9DB1-61E2F2AB089F Q33643589-C3853730-F757-4991-9E34-B25995E55E7A Q33936347-BD6D84D2-0F2A-4918-AAD2-5150DF589311 Q34046354-C683EF62-A701-4FE3-8640-2BAFA1F49CC8 Q34454393-BF45D803-7DAC-4785-BF61-EF8C723B2094 Q34746630-6D1AEB72-B483-4CBB-BFC3-36534E918067 Q34979826-3CD505DF-5174-4D0D-890D-63EB5320D80F Q35020182-726CF5EF-B0AB-485D-93F8-562B6F7D8058 Q35202586-7A954A4B-3932-41D5-916C-99A6784CDCBD Q35569636-9217484F-E2B8-4481-B97E-7F42B858E209 Q35867093-49D5D333-51F1-4C1D-836D-37D437936B94 Q35921438-9BDDEB73-39F7-435F-975A-5E900D5FF6B2 Q36111546-E92702B8-543E-4341-911A-51399A5AA613 Q36111747-73CB5F8A-563F-41BB-B55C-1ABB895D155B Q36137301-CE2501B4-8BDE-4DFF-8F59-69F2C5AF9020 Q37279515-286C2E36-8BD4-473D-83C0-A8D244D97BBF Q37647989-A4D29801-3FBD-46BD-8775-CDDE8461CFD0 Q37683060-9861D053-C41D-4B0B-9518-79AC2D47A9F3 Q37698148-790DDB0B-D5AF-488D-B6D6-6F87518B0CD3 Q37912174-941093E6-9BBC-45E1-943E-82EA4233121A Q38756851-5879B5FD-5750-4E49-BEBC-BEC26779B4B7 Q38875190-D9E1577E-6C43-4BAA-B823-EB7EE7D48A57 Q39294662-D3FEB112-C2C6-428A-9752-D6F045E1E268 Q41811378-5075DB15-B4E6-4F56-B6A3-E31EDD967371 Q42486904-72C59457-3E44-4BE1-9935-2834CB57B027 Q46193918-F9818816-1EC9-45F4-9D1F-915EDA416CEE Q47155189-6C6D0A95-C8E7-44C2-B0BB-BB772F3BEE40 Q48918417-6ADB1D1F-6129-4D18-8DED-9DD80AA1D8E9 Q50962404-2911EF37-07B9-4644-913A-CA0B39F1D08A Q55313635-DAF8DEAD-A0D9-4898-94B0-C1766E0E49B6

P2860

Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.

http://www.wikidata.org/entity/Q34084791

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of long-term memantine ...... ce, a model for Down syndrome.

@ast

Effects of long-term memantine ...... ce, a model for Down syndrome.

@en

Effects of long-term memantine ...... ce, a model for Down syndrome.

@nl

type

label

Effects of long-term memantine ...... ce, a model for Down syndrome.

@ast

Effects of long-term memantine ...... ce, a model for Down syndrome.

@en

Effects of long-term memantine ...... ce, a model for Down syndrome.

@nl

prefLabel

Effects of long-term memantine ...... ce, a model for Down syndrome.

@ast

Effects of long-term memantine ...... ce, a model for Down syndrome.

@en

Effects of long-term memantine ...... ce, a model for Down syndrome.

@nl

P1433

Q34084791-94DC04C8-6D29-4B8D-A7F5-954492072A8C

P1476

Q34084791-3CC2D515-381D-446F-9470-2D9D5C0DF90B

P2093

Q34084791-015AE695-9F16-4E76-A8CA-98CA2B80FBD2

Q34084791-A7C76ECB-AF1A-4ED3-86B8-A6733EBC5C23

Q34084791-FADBE3D3-EE3D-4785-B792-76746B12779B

Q34084791-FC2C0044-C6F7-4774-9846-82869AA72038

P2860

Q34084791-060DC1FC-6C87-433C-8D1C-6ADDF54EA160

Q34084791-07AE8B61-D224-4F0A-B2FE-871E70126493

Q34084791-0849B838-DE85-4539-B97F-E0AF590503A8

Q34084791-09121A03-80A3-4344-A473-AEFC4E6E3C01

Q34084791-09AE7C12-AE36-4ED2-9552-A8880FA2D11D

Q34084791-0D927951-5E21-4882-90AB-B035C25BDBFF

Q34084791-0E709A72-38DC-49E8-B99C-D784FC66DE50

Q34084791-14D74D98-CFB4-4DF8-AB7F-972BB431C53F

Q34084791-19B787AC-17FA-4C65-9BDD-C1CAC026F2C3

Q34084791-1F540572-9EA4-4D94-AE92-166E3422E9CD

P304

Q34084791-73F2AA52-5D85-40EE-9AEC-12CE3FD5131C

P31

Q34084791-3A7E91AD-9CAF-4024-A139-313FEB708EFE

P356

Q34084791-E3365C04-D619-4552-97E6-D6E4B1505F86

P407

Q34084791-A8B2A480-6F59-43C9-BE84-2FEE3FF5999D

P433

Q34084791-C99386E3-81F8-4592-92C3-A7AC6D983653

P478

Q34084791-B6BFA884-3928-432E-A9B6-CC73A92E0A47

P577

Q34084791-17328AB1-B349-4687-BD6C-FC6287E435FD

P5875

Q34084791-7F4064D0-45B3-42A7-A73A-013B290A1763

P698

Q34084791-AEB3486F-7D58-4123-A54A-054EB05D4384

P932

Q34084791-1C5BF041-334E-42AD-B09B-E0DB3B570700

P356

J.BBR.2010.03.036

P1433

Behavioural Brain Research

P1476

Effects of long-term memantine ...... ce, a model for Down syndrome.

@en

P2093

Ann-Charlotte Granholm

http://www.w3.org/2001/XMLSchema#string

Heather Bimonte-Nelson

http://www.w3.org/2001/XMLSchema#string

Heather Boger

http://www.w3.org/2001/XMLSchema#string

Jason Lockrow

http://www.w3.org/2001/XMLSchema#string

P2860

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine.

The medial temporal lobe

Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice.

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials.

Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion.

Cholinesterase inhibitors stabilize Alzheimer's disease.

Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome.

Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane.

P304

610-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBR.2010.03.036

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

221

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42975114

http://www.w3.org/2001/XMLSchema#string

P698

20363261

http://www.w3.org/2001/XMLSchema#string

P932

2928411

http://www.w3.org/2001/XMLSchema#string